The RASGRP3, a RAS activator is known to play a role in several cancers, including breast (Nagy et al., 2014), papillary thyroid (Qiu et al., 2017), and prostate cancers (Yang et al., 2010). Here, RASGRP3 is linked to prostate carcinoma.